Dr. Arturo Loaiza-Bonilla chairing a session now at #ASCO26 on Tech that Scales: #AI & Digital Tools for Cancer Care in LMICs with panelists Dr. Partha Basu & Dr. Sanjeev Arora. Related material from #ASCOEdBook: https://bit.ly/4331xeN
Arturo LoAIza-Bonilla, MD MSEd
@drbonillaonc.bsky.social
Co-founder @MassiveBio | Chief Hem/Onc @mystlukes | Using #tech #AI & #genomics to fight cancer at global scale 🌎 🚀 🧬 🖥️ - My Opinions only
AI in Oncology Depends on Transparent and Verifiable Evidence - Arturo LoAlza-Bonilla @drbonillaonc.bsky.social oncodaily.com/voices/artur... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Arturo LoAlza-Bonilla: AI in Oncology Depends on Transparent and Verifiable Evidence - OncoDaily
Arturo LoAlza-Bonilla: AI in Oncology Depends on Transparent and Verifiable Evidence / AI, Arturo Bonilla, Arturo Loaiza-Bonilla, cancer, Chad Levitt, Chadi
oncodaily.com
Solving the Clinical Trial Enrollment Paradox Using AI and Big Data - Arturo LoAIza-Bonilla @drbonillaonc.bsky.social oncodaily.com/voices/artur... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Arturo LoAIza-Bonilla: Solving the Clinical Trial Enrollment Paradox Using AI and Big Data - OncoDaily
Arturo LoAIza-Bonilla: Solving the Clinical Trial Enrollment Paradox Using AI and Big Data / Arturo Loaiza-Bonilla, ASCO, cancer, OncoDaily, Oncology
oncodaily.com
Perspective by Arturo Loaiza-Bonilla, MD, MSEd, FACP, and Scott Penberthy, PhD : Harnessing Moravec’s Paradox in Health Care: A New Era of Collaborative Intelligence nejm.ai/4jSWaVV @drbonillaonc.bsky.social #AI #MedSky #MLSky
#asco25 joint @ascocancer.bsky.social @myesmo.bsky.social session on “Biomarker-driven Therapeutics: Translating Innovation into Practice” @drbonillaonc.bsky.social
Red lens sunglasses can enhance contrast and depth perception, may also reduce eye fatigue by filtering certain wavelengths and improving visual comfort. After so much screen time in preparation for #ASCO25 this really helps! See you in Chicago!! @ASCO @mystlukes @americancancersoc.bsky.social
Performance Evaluation of an AI-powered System for Clinical Trial Eligibility Using mCODE Data Standards - Yan Leyfman @yleyfman.bsky.social @drbonillaonc.bsky.social @massive-bio.bsky.social oncodaily.com/blog/yan-ley... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI
Yan Leyfman: Performance Evaluation of an AI-powered System For Clinical Trial Eligibility Using mCODE Data Standards - OncoDaily
Yan Leyfman: Performance Evaluation of an AI-powered System For Clinical Trial Eligibility Using mCODE Data Standards / and Cagatay Culcuoglu, Arturo
oncodaily.com
ASCO/ESMO Joint Session at ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics dailynews.ascopubs.org/do/asco-esmo...
ASCO Daily News
dailynews.ascopubs.org
Filming day at St. Luke’s! 🎥 From clinical trials to AI-powered care, we’re showcasing how we fight cancer with heart and innovation. 🚀 16 hospitals. Robotic surgery. Advanced radiation. Multiomics + bi-specifics. The most wired health system in the U.S. All for you. #StLukesProud
Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology | American Society of Clinical Oncology Educational Book ascopubs.org/doi/full/10.... #ASCO25 @drbonillaonc.bsky.social
How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support - Arturo LoAIza-Bonilla @drbonillaonc.bsky.social oncodaily.com/blog/arturo-... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #ASCO25
Arturo LoAIza-Bonilla: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support - OncoDaily
Arturo LoAIza-Bonilla: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support / AI, Arturo Loaiza-Bonilla, ASCO,
oncodaily.com
Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology | American Society of Clinical Oncology Educational Book ascopubs.org/doi/full/10....
Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology
Artificial intelligence (AI) is transforming multidisciplinary oncology at an unprecedented pace, redefining how clinicians detect, classify, and treat cancer. From earlier and more accurate diagnoses...
ascopubs.org
Thrilled to see my latest article featured in the Spring 2025 issue of llOncolytics Today! 🌟 “Closing the Gaps in Oncology: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support” #ASCO25. See you in Chicago! #PrescreeningHubs
Moravec’s paradox also discussed in context of AI & healthcare by @pmarca.tweet.pub in recent thoughtful @a16z.bsky.social pcast, as I wrote about here: timmermanreport.com/2025/02/the-...
The Future of AI and Health, Part II: Andreessen and Colleagues Weigh In - TimmermanReport.com
Part I of this series is here. Over its 15 years of existence, the Andreessen Horowitz (“A16z”) venture capital firm has evolved from a media-savvy disruptive upstart to an exceedingly well-heeled inc...
timmermanreport.com
Eric Topol@erictopol.bsky.social · last yr.A good discussion of Moravec's paradox in healthcare @NEJM_AI ai.nejm.org/doi/full/10....
A good discussion of Moravec's paradox in healthcare @NEJM_AI ai.nejm.org/doi/full/10....
Harnessing Moravec’s Paradox in Health Care: A New Era of Collaborative Intelligence
Artificial intelligence excels at complex data analytics, yet struggles with nuanced, sensorimotor tasks that humans perform almost effortlessly — a dichotomy encapsulated by Moravec’s paradox. By ...
ai.nejm.org
Thrilled! Our @ai.nejm.org NEJM AI perspective “Harnessing Moravec’s Paradox in Health Care” - is now live. Grateful for brilliant co-author & friend Scott Penberthy (@scottpenberthy) of @GoogleCloud. Onward to truly collaborative intelligence! 🔗 ai.nejm.org/stoken/defau...
Full day of CME discussing the top research from ASCOGI25 - @drbonillaonc.bsky.social @ascocancer.bsky.social oncodaily.com/url/269641 #OncoDaily #Oncology #Cancer #Health #Medicine #ASCOGI25
Arturo LoAIza-Bonilla: Full day of CME discussing the top research from ASCOGI25 - OncoDaily
Arturo LoAIza-Bonilla: Full day of CME discussing the top research from ASCOGI25 / American Society of Clinical Oncology, Arturo Loaiza-Bonilla, ASCO,
oncodaily.com
www.cancernetwork.com/view/investi... - Dr. Regina Barzilay PhD, Ketan Badani MD FRCS and I share some insights on it’s future implementation in cancer care | St. Luke's University Health Network | Massive Bio | Massachusetts Institute of Technology | Mount Sinai Health System #AI #cancer
Investigating the Emergence of Artificial Intelligence on Oncologic Practice
As artificial intelligence has arrived in the oncology field, experts discuss how this new technology can have implications for transforming clinical practice.
cancernetwork.com
Great representation of @mystlukes at @LmsaNational NE 2025 meeting!! Appreciate the invitation to hopefully inspire future generations of physicians. Even better when Dr. Israel Zighelboim as faculty! #stlukesproud @MassiveBio | @TUMedResearch @TempleUniv #AI
LIVE today discussing the urgent challenges in cancer research and clinical trials due to funding cuts. AI, innovation, & collaboration are key to overcoming these obstacles and driving progress in the field. @MassiveBio Tune in now for key insights! 🎥👇 📺 Watch live: www.youtube.com/watch?v=ar5q...
NIH funding cuts threaten clinical trials and patient access to life-saving treatments. Our Co-Founder & CMO, @drbonillaonc.bsky.social, shares how we can adapt and innovate. Read the open letter 👉 bit.ly/3CyOtnP #Cancer #cancerclinical #clinicaltrials #OpenLetter
An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community
February 2025 Dear Colleagues, In light of the recent developments regarding the The National Institutes of Health’s (NIH) abrupt reduction of indirect cost rates—from historical levels approaching 50...
bit.ly
Massive Bio remains committed to accelerating cancer research and expanding clinical trial access amid the uncertainty surrounding recent NIH funding cuts. The mission to ensure equitable access to innovative cancer care is more critical than ever. Read the full press release: bit.ly/3CIRXEg
www.onclive.com/view/artific... This is a long format grand rounds video for OncLive where I share about the advent of #ArtificialIntelligence in #CancerCare and #ClinicalTrials - hope you find it interesting @massive-bio.bsky.social
Artificial Intelligence in Cancer Care and Clinical Trials
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.
onclive.com
Proud to be in California at the AMA/RUC meeting, representing American Society of Clinical Oncology (ASCO) and all U.S. oncology practices to champion equitable access and fair reimbursement for lifesaving cancer therapies. Thank you to our dedicated ASCO staff for your hard work, and to SLUHN!
Proudest moment for Massive Bio on being recognized by The White House Cancer Moonshot for our efforts in helping cancer patients to transform access clinical trials with our AI-enabled platform and scalable pre-screening hubs. Massive thank you to team and all our partners who make this possible!!
Fascinating fire chat with @bryan_johnson during our Scrub Capital mtg. Kudos to being bold investing in efforts to understand longevity, epigenetic, biomarkers, aging clocks, human physiology. At @MassiveBio we are taking also a bold innovative approach to transform clinical trials & research!! 🚀
Starting 2025 with site visits across our 15-hospitals at @mystlukes and an interview at @WNEP to discuss Surgeon General’s report on the link between alcohol and cancer risks. Committed to awareness and collaboration for screening and access @AmericanCancer - @ASCO - @MassiveBio lnkd.in/e9MwVQhd
“Imagine a world where every patient, regardless of geography or socioeconomic status, has access to the best treatment options available – a world where a diagnosis does not come with a stigma or an expiration date, but rather with hope and personalized pathways to wellness”
